Edition:
United States

Profile: Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.61USD
26 May 2017
Change (% chg)

$-0.06 (-3.59%)
Prev Close
$1.67
Open
$1.66
Day's High
$1.67
Day's Low
$1.59
Volume
136,637
Avg. Vol
249,950
52-wk High
$3.31
52-wk Low
$1.30

Idera Pharmaceuticals, Inc., incorporated on August 24, 2005, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200.

The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. The Company's TLR agonist lead drug candidate IMO-2125 is an agonist of TLR9. Its TLR antagonist lead drug candidate is IMO-8400, which is an antagonist of TLR7, TLR8 and TLR9. It is evaluating IMO-2125 for the treatment by intra-tumoral injection of multiple oncology indications both in combination with checkpoint inhibitors and as monotherapy. It is developing IMO-8400 for the treatment of a rare disease called dermatomyositis. It is developing IMO-2125 for use in combination with checkpoint inhibitors for the treatment of patients with anti-PD1 refractory metastatic melanoma. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

The Company has designed 3GA oligonucleotides to specifically address challenges associated with earlier generation antisense and RNAi technologies. The Company has developed a second synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9, IMO-9200, as a drug candidate for potential use in selected autoimmune disease indications. In addition to its TLR-targeted and 3GA patent portfolios, it holds licenses to patents and patent applications related to antisense technology.

The Company competes with Dynavax, Mologen AG, BioLineRx Ltd., Innate Immunotherapeutics Ltd., VentiRx Pharmaceuticals Inc., Telormedix S.A., Gilead Sciences Inc., GlaxoSmithKline plc, AstraZeneca plc, Checkmate Pharmaceuticals, Inc., Hoffmann-La Rochem, Alnylam, Dicerna, Miragen, Ionis Pharmaceuticals, Inc. and Biogen.

Company Address

Idera Pharmaceuticals Inc

167 Sidney St
CAMBRIDGE   MA   02139-4237
P: +1617.6795500
F: +1617.6795592

Company Web Links